Madam Speaker, earlier I raised the issue that this U.K.-Canada trade deal does not address the ISDS provisions. That is not the only concern. It also does not address the upward pressure on pharmaceutical drug costs related to the patent issue. The government member responded by saying that this is a transitional deal, yet there is no sunset clause to this transitional deal.
Does the member think that it is appropriate to not have a sunset clause to ensure that we will have an end date with negotiations?